{"entity":{"id":"epigenetics","kind":"section","name":"Epigenetic & Transcriptional Therapy","aka":[],"tldr":"Epigenetic and transcriptional therapy changes how genes are read rather than the genes themselves.","summary":"Epigenetic and transcriptional therapy changes how genes are read rather than the genes themselves. The section brings together DNMT and HDAC inhibitors used in haematological malignancies, EZH2 inhibitors, IDH inhibitors, menin inhibitors such as revumenib, BET inhibitors and emerging transcription-factor degraders, a class mostly established in blood cancers with solid tumours catching up. Linked records include the technologies epigenetic drugs and epigenetic editing, the term hypomethylating agents, the paper on the 2022 Hallmarks of Cancer, and the institutions USC Norris and Ruijin Hospital. Companies pointing here are Kura Oncology, Taiho Oncology, Servier, Syndax Pharmaceuticals, MorphoSys and Chipscreen Biosciences.","asOf":"2026-09-04","links":[{"label":"NCI: Dictionary of Cancer Terms: epigenetics","url":"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/epigenetics"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"order":13,"icon":"helix"},"route":"/fronts/epigenetics/","neighbours":{"company":[{"id":"amphista-therapeutics","kind":"company","name":"Amphista Therapeutics","route":"/companies/amphista-therapeutics/"},{"id":"chipscreen","kind":"company","name":"Chipscreen Biosciences","route":"/companies/chipscreen/"},{"id":"foghorn-therapeutics","kind":"company","name":"Foghorn Therapeutics","route":"/companies/foghorn-therapeutics/"},{"id":"k36-therapeutics","kind":"company","name":"K36 Therapeutics","route":"/companies/k36-therapeutics/"},{"id":"kura-oncology","kind":"company","name":"Kura Oncology","route":"/companies/kura-oncology/"},{"id":"morphosys","kind":"company","name":"MorphoSys (Novartis)","route":"/companies/morphosys/"},{"id":"oric-pharmaceuticals","kind":"company","name":"ORIC Pharmaceuticals","route":"/companies/oric-pharmaceuticals/"},{"id":"prelude-therapeutics","kind":"company","name":"Prelude Therapeutics","route":"/companies/prelude-therapeutics/"},{"id":"proxygen","kind":"company","name":"Proxygen","route":"/companies/proxygen/"},{"id":"servier","kind":"company","name":"Servier","route":"/companies/servier/"},{"id":"syndax","kind":"company","name":"Syndax Pharmaceuticals","route":"/companies/syndax/"},{"id":"taiho-oncology","kind":"company","name":"Taiho Oncology (Otsuka)","route":"/companies/taiho-oncology/"},{"id":"treeline-biosciences","kind":"company","name":"Treeline Biosciences","route":"/companies/treeline-biosciences/"}],"paper":[{"id":"paper-hallmarks-new-dimensions-cancer-discov-2022","kind":"paper","name":"Hallmarks of Cancer 2022: adding phenotypic plasticity, epigenetic reprogramming, microbiomes and senescent cells","route":"/key-papers/paper-hallmarks-new-dimensions-cancer-discov-2022/"},{"id":"paper-mu-sox2-lineage-plasticity-science-2017","kind":"paper","name":"SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer","route":"/key-papers/paper-mu-sox2-lineage-plasticity-science-2017/"},{"id":"paper-grasso-mutational-landscape-lethal-crpc-nature-2012","kind":"paper","name":"The mutational landscape of lethal castration-resistant prostate cancer","route":"/key-papers/paper-grasso-mutational-landscape-lethal-crpc-nature-2012/"}],"technology":[{"id":"epigenetic-drugs","kind":"technology","name":"Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET)","route":"/technologies/epigenetic-drugs/"},{"id":"epigenetic-editing","kind":"technology","name":"Epigenetic editing (durable gene silencing)","route":"/technologies/epigenetic-editing/"},{"id":"kat6-inhibitors","kind":"technology","name":"KAT6 inhibitors","route":"/technologies/kat6-inhibitors/"},{"id":"lsd1-inhibitors","kind":"technology","name":"LSD1 inhibitors","route":"/technologies/lsd1-inhibitors/"}],"term":[{"id":"hma","kind":"term","name":"Hypomethylating agents (azacitidine, decitabine)","route":"/terms/hma/"}],"institution":[{"id":"ruijin-hospital","kind":"institution","name":"Ruijin Hospital, Shanghai Jiao Tong University","route":"/institutions/ruijin-hospital/"},{"id":"usc-norris","kind":"institution","name":"USC Norris Comprehensive Cancer Center","route":"/institutions/usc-norris/"}],"roadmap":[{"id":"epigenetics-roadmap","kind":"roadmap","name":"Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome","route":"/roadmaps/epigenetics-roadmap/"}]}}